Understanding how injection drug use affects HIV treatment outcomes
Defining the impact of injection drug use on antiretroviral therapy and HIV treatment outcomes: an (epi)genomic approach
This study is looking at how using injection drugs might affect the success of HIV treatment, and it’s for people living with HIV to help understand how their drug use could change their health and treatment outcomes.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Yale University NIH-funded |
| Lab location | 1 site (New Haven, United States) |
| Project ID | NIH-10448415 on NIH RePORTER |
What this research studies
This research investigates the impact of injection drug use on the effectiveness of antiretroviral therapy in individuals living with HIV. It aims to identify genomic changes associated with injection drug use that may influence health outcomes for these patients. By comparing the genetic profiles of HIV-infected individuals who inject drugs with those who do not, the study seeks to uncover how these factors affect treatment responses and overall health. The research employs advanced genomic techniques to analyze DNA methylation and gene expression in blood samples.
Who could benefit from this research
Good fit: Ideal candidates for this research are HIV-infected individuals who have a history of injection drug use and are currently receiving antiretroviral therapy.
Not a fit: Patients who are HIV-negative or those who do not use injection drugs may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment strategies for HIV-infected individuals who inject drugs, enhancing their health outcomes.
How similar studies have performed: Previous research has indicated that genomic factors can significantly influence health outcomes in HIV-infected populations, suggesting that this approach may yield valuable insights.
Where this research is happening
New Haven, United States
- Yale University — New Haven, United States (Active)
Researchers
- Principal investigator: Xu, Ke — Yale University
- Study coordinator: Xu, Ke
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.